Literature DB >> 7192824

Stable remissions in myasthenia gravis.

M C Perez, W L Buot, C Mercado-Danguilan, Z G Bagabaldo, L D Renales.   

Abstract

Forty-two myasthenic patients received a total of 7.6 to 130 gm of cyclophosphamide over 2 to 37 months; 33 received prednisone concomitantly. Twenty-five (60%) are presently asympatomatic. Seventy-four percent improved after 1 month of therapy. Fifty-eight percent of those treated for a year, 86% of those treated for 2 years, and 100% of those treated for 32 months were asymptomatic. Based on our definition of remission (asymptomatic for at least 6 months without medication), 12 of the 16 patients (75%) followed for at least 18 months were in remission. Cyclophosphamide may have more specific therapeutic effects than other immunosuppressive drugs used to treat myasthenia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7192824     DOI: 10.1212/wnl.31.1.32

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.

Authors:  R Mantegazza; C Antozzi; D Peluchetti; A Sghirlanzoni; F Cornelio
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

Review 3.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Treatment of myasthenia gravis.

Authors:  D P Richman
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

5.  Do true remissions in myasthenia really exist? An electrophysiological study.

Authors:  B Emeryk; K Rowińska; T Nowak-Michalska
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

6.  Immunosuppressive treatment for juvenile myasthenia gravis.

Authors:  B Badurska; B Ryniewicz; H Strugalska
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

Review 7.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

9.  Treatment of myasthenia gravis based on its immunopathogenesis.

Authors:  Jee Young Kim; Kee Duk Park; David P Richman
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

10.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.